Fresenius Medical Care provides dialysis care services related to the dialysis treatment a patient receives with end stage renal disease, and other health care services. The company was founded in 1996 and is based in Bad Homburg, Germany.
FMS Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for FMS, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Fresenius Medical Care AG & Co KGaA ranked in the 63th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. As for the metrics that stood out in our discounted cash flow analysis of Fresenius Medical Care AG & Co KGaA, consider:
48% of the company's capital comes from equity, which is greater than merely 22.1% of stocks in our cash flow based forecasting set.
Fresenius Medical Care AG & Co KGaA's weighted average cost of capital (WACC) is 6%; for context, that number is higher than merely 1.59% of tickers in our DCF set.
Relative to other stocks in its sector (Healthcare), Fresenius Medical Care AG & Co KGaA has a reliance on debt greater than 89.12% of them.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as FMS, try DVA, FZMD, ANTM, CHE, and NVO.
DUBLIN, Sept. 28, 2020 /PRNewswire/ -- The "Peritoneal Dialysis Market - Global Outlook & Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering. The peritoneal dialysis market by revenue is expected to grow at a CAGR of over 6% during the period 2019-2025 Market…
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Vifor Fresenius Medical Care Renal Pharma's Velphoro (mixture of polynuclear iron ((III))-oxyhydroxide, sucrose and starches) for the control of serum phosphorus levels in pediatric patients at least two years old with chronic kidney disease ((CKD))...
HONG KONG--(BUSINESS WIRE)-- #chronickidneydisease--Fresenius Medical Care, the world’s leading provider of dialysis products and services, today announced the launch of the organization’s first World Patient Safety Day initiative to raise awareness of the importance of ultrapure dialysis fluid for developing economies across Asia Pacific. On 17 September each year, the World Health Organization (WHO), international partners and all countries commemorate World Patient Safety Day: a day that aims to increase global awa